These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 26388043)

  • 1. The European Long-range Research Initiative (LRI): A decade of contributions to human health protection, exposure modelling and environmental integrity.
    de Boer J; Fritsche E; Schoeters G; Kimber I
    Toxicology; 2015 Nov; 337():83-90. PubMed ID: 26388043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human biomonitoring activities--programmes by industry.
    Boogaard PJ
    Int J Hyg Environ Health; 2007 May; 210(3-4):259-61. PubMed ID: 17275410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification, assessment and management of "endocrine disruptors" in wildlife in the EU substance legislation--discussion paper from the German Federal Environment Agency (UBA).
    Frische T; Bachmann J; Frein D; Juffernholz T; Kehrer A; Klein A; Maack G; Stock F; Stolzenberg HC; Thierbach C; Walter-Rohde S
    Toxicol Lett; 2013 Dec; 223(3):306-9. PubMed ID: 23500481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European Union research in support of environment and health: Building scientific evidence base for policy.
    Karjalainen T; Hoeveler A; Draghia-Akli R
    Environ Int; 2017 Jun; 103():51-60. PubMed ID: 28384507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human biomonitoring as a pragmatic tool to support health risk management of chemicals--examples under the EU REACH programme.
    Boogaard PJ; Hays SM; Aylward LL
    Regul Toxicol Pharmacol; 2011 Feb; 59(1):125-32. PubMed ID: 20933039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of research on endocrine disruption for the environmental risk assessment, regulation and monitoring of chemicals in the European Union.
    Matthiessen P; Johnson I
    Environ Pollut; 2007 Mar; 146(1):9-18. PubMed ID: 16996184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk assessment of endocrine active chemicals: identifying chemicals of regulatory concern.
    Bars R; Fegert I; Gross M; Lewis D; Weltje L; Weyers A; Wheeler JR; Galay-Burgos M
    Regul Toxicol Pharmacol; 2012 Oct; 64(1):143-54. PubMed ID: 22735369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic approach for designing a HBM pilot study for Europe.
    Becker K; Seiwert M; Casteleyn L; Joas R; Joas A; Biot P; Aerts D; Castaño A; Esteban M; Angerer J; Koch HM; Schoeters G; Den Hond E; Sepai O; Exley K; Knudsen LE; Horvat M; Bloemen L; Kolossa-Gehring M;
    Int J Hyg Environ Health; 2014 Mar; 217(2-3):312-22. PubMed ID: 23928002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human biomonitoring and the INSPIRE directive: spatial data as link for environment and health research.
    Smolders R; Casteleyn L; Joas R; Schoeters G
    J Toxicol Environ Health B Crit Rev; 2008 Oct; 11(8):646-59. PubMed ID: 18821423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Endocrine disrupters: from research to risk assessment].
    Mantovani A; La Rocca C; Maranghi F
    Epidemiol Prev; 2009; 33(1-2):5-7. PubMed ID: 19585867
    [No Abstract]   [Full Text] [Related]  

  • 12. White paper on the promotion of an integrated risk assessment concept in European regulatory frameworks for chemicals.
    Wilks MF; Roth N; Aicher L; Faust M; Papadaki P; Marchis A; Calliera M; Ginebreda A; Andres S; Kühne R; Schüürmann G;
    Sci Total Environ; 2015 Jul; 521-522():211-8. PubMed ID: 25841074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential application of ecological models in the European environmental risk assessment of chemicals. I. Review of protection goals in EU directives and regulations.
    Hommen U; Baveco JM; Galic N; van den Brink PJ
    Integr Environ Assess Manag; 2010 Jul; 6(3):325-37. PubMed ID: 20821697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The European Union risk assessment on zinc and zinc compounds: the process and the facts.
    Bodar CW; Pronk ME; Sijm DT
    Integr Environ Assess Manag; 2005 Nov; 1(4):301-19. PubMed ID: 16639898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International scientists' priorities for research on pharmaceutical and personal care products in the environment.
    Rudd MA; Ankley GT; Boxall AB; Brooks BW
    Integr Environ Assess Manag; 2014 Oct; 10(4):576-87. PubMed ID: 24954797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revising the EU strategy on endocrine disruptors: nearing a decisive moment.
    van Vliet L; Jensen GK
    J Epidemiol Community Health; 2013 May; 67(5):383-4. PubMed ID: 23144491
    [No Abstract]   [Full Text] [Related]  

  • 17. European union system for the evaluation of substances: the second version.
    Attias L; Boccardi P; Boeije G; Brooke D; de Bruijn J; Comber M; Dolan B; Fischer S; Heinemeyer G; Koch V; Lijzen J; Müller B; Murray-Smith R; Rikken M; Tadeo J; Vermeire T
    Chemosphere; 2005 Apr; 59(4):473-85. PubMed ID: 15788170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of chemical mixtures in public health practice.
    de Rosa CT; El-Masri HA; Pohl H; Cibulas W; Mumtaz MM
    J Toxicol Environ Health B Crit Rev; 2004; 7(5):339-50. PubMed ID: 15371239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Policy recommendations and cost implications for a more sustainable framework for European human biomonitoring surveys.
    Joas A; Knudsen LE; Kolossa-Gehring M; Sepai O; Casteleyn L; Schoeters G; Angerer J; Castaño A; Aerts D; Biot P; Horvat M; Bloemen L; Reis MF; Lupsa IR; Katsonouri A; Cerna M; Berglund M; Crettaz P; Rudnai P; Halzlova K; Mulcahy M; Gutleb AC; Fischer ME; Becher G; Fréry N; Jensen G; Van Vliet L; Koch HM; Den Hond E; Fiddicke U; Esteban M; Exley K; Schwedler G; Seiwert M; Ligocka D; Hohenblum P; Kyrtopoulos S; Botsivali M; DeFelip E; Guillou C; Reniero F; Grazuleviciene R; Veidebaum T; Mørck TA; Nielsen JK; Jensen JF; Rivas TC; Sanchez J; Koppen G; Smolders R; Kozepesy S; Hadjipanayis A; Krskova A; Mannion R; Jakubowski M; Fucic JA; Pereira-Miguel J; Gurzau AE; Jajcaj M; Mazej D; Tratnik JS; Lehmann A; Larsson K; Dumez B; Joas R
    Environ Res; 2015 Aug; 141():42-57. PubMed ID: 25526891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The legal failure to prevent subclinical developmental toxicity.
    Cranor C
    Basic Clin Pharmacol Toxicol; 2008 Feb; 102(2):267-73. PubMed ID: 18226082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.